ライフサイエンスコーパス: sudden death

1 y failure, one thromboembolic event, and one sudden death).

2 syncope, 7 near-drowning, and 3 resuscitated sudden death).

3 that SCT is associated with exertion-related sudden death.

4 entricular arrhythmias and can predispose to sudden death.

5 Illicit fentanyl use is associated with sudden death.

6 odels to identify patients at higher risk of sudden death.

7 f internal cardiac defibrillators to prevent sudden death.

8 diomyopathy, heart failure, arrhythmias, and sudden death.

9 ed by aortic dilation and rupture leading to sudden death.

10 are associated with cardiac arrhythmias and sudden death.

11 cular death, HF hospitalization, and aborted sudden death.

12 ardiomyopathy, Takotsubo cardiomyopathy, and sudden death.

13 patients with inherited cardiomyopathies and sudden death.

14 chemic changes were noted in SCA mice before sudden death.

15 (HCM), largely because of the possibility of sudden death.

16 ic disease responsible for heart failure and sudden death.

17 heart disease, 528 from stroke, and 893 from sudden death.

18 ar diastolic heart disease, dysrhythmia, and sudden death.

19 nostic value for both cardiac death (CD) and sudden death.

20 myopathies complicated by frequent premature sudden death.

21 ith all-cause mortality, vascular death, and sudden death.

22 T syndrome (LQTS) is associated with risk of sudden death.

23 nfluence the risk of cardiac arrhythmias and sudden death.

24 d individuals to ventricular arrhythmias and sudden death.

25 aches designed to restore life to victims of sudden death.

26 block, presenting clinically as syncope, and sudden death.

27 isk of arrhythmia, premature RV failure, and sudden death.

28 r, associated with an increased incidence of sudden death.

29 s to mitral regurgitation, heart failure and sudden death.

30 -four children (60%) had a family history of sudden death.

31 (2+) sensitivity, and high susceptibility to sudden death.

32 ng arterial aneurysms, which may manifest as sudden death.

33 some patients to debilitating morbidity and sudden death.

34 n artery that can lead to vessel rupture and sudden death.

35 se of ventricular tachyarrhythmias (VTs) and sudden death.

36 hythmogenic disorder that causes syncope and sudden death.

37 overly conservative management can result in sudden death.

38 e 2 (SENP2) develop spontaneous seizures and sudden death.

39 rance, risk of progressive heart failure and sudden death.

40 ical mortality was most frequently caused by sudden death.

41 cytes, cardiac dysfunction, arrhythmias, and sudden death.

42 ventricular arrhythmias, heart failure, and sudden death.

43 8) and/or TdP (n=68; 11% fatal), and 99 with sudden death.

44 s, developmental delay, and elevated risk of sudden death.

45 and increased risk of cardiac arrhythmia and sudden death.

46 ding symptoms or recognized risk factors for sudden death.

47 verse effects, including rare occurrences of sudden death.

48 ar arrhythmias leading to cardiac arrest and sudden death.

49 iers of hERG/R148W may be at risk of cardiac sudden death.

50 ffected individuals to fatal arrhythmias and sudden death.

51 d individuals to ventricular arrhythmias and sudden death.

52 opulations are at greater risk to succumb to sudden death.

53 milial evaluation following a young person's sudden death.

54 often of cardiovascular causes, particularly sudden death.

55 iologic studies in MVP patients with aborted sudden death.

56 ch patient) and how to treat them to prevent sudden death.

57 ypoketotic hypoglycemia, cardiomyopathy, and sudden death.

58 s ratio=1.4-4.7; P<0.05) with aLQTS, TdP, or sudden death.

59 creasing the risk of cardiac arrhythmias and sudden death.

60 ed susceptibility to cardiac arrhythmias and sudden death.

61 hich can lead to ventricular arrhythmias and sudden death.

62 enotypes, including spontaneous seizures and sudden death.

63 fentanyl-induced ventricular arrhythmias and sudden death.

64 nges modeling bipolar disorder, epilepsy and sudden death.

65 n myocardial territory supplied by a SVG, or sudden death.

66 CI) increases the risk of cardiomyopathy and sudden death.

67 uid index value) were seen in 62.8% cases of sudden deaths.

68 sports participation (2), family history of sudden death (1), and other (1).

69 tient-years; 1.19; 1.03-1.39, p=0.0201), and sudden death (1.68 vs 1.12 events per 100 patient-years;

70 of 2 years, 11 AACEs (2.5%) were detected: 5 sudden deaths (1.1%) and 6 spontaneous ventricular tachy

71 Nearly all patients with sudden death (14 of 15) had abnormal cardiac dimensions

72 (9.3%): 37 (35%) due to HF, 25 (23%) due to sudden death, 15 (14%) due to other cardiovascular (CV)

73 patient (10 outpatient, 985 hospitalized, 17 sudden death), 25 food, 18 dust/soils, and 35 other stra

74 ted arrhythmia (3.4%), and family history of sudden death (4.2%) were uncommon.

75 arrhythmias are rare but are associated with sudden death; 9) early- and late-onset ND abnormalities

76 Although sudden death accounted for approximately 25% to 30% of d

77 There was a 44% decline in the rate of sudden death across the trials (P=0.03).

78 Sudden death after surgery for atrial septal defect, ven

79 variability (HRV) is a major risk factor for sudden death and cardiovascular disease.

80 polarization (ER) pattern is associated with sudden death and has been shown to be heritable.

81 was driven by reductions in out-of-hospital sudden death and hospitalized ST-segment-elevation myoca

82 e was driven by decreases in out-of-hospital sudden death and hospitalized ST-segment-elevation myoca

83 es have shown an association between risk of sudden death and left ventricular maximal wall thickness

84 Fallot was associated with a minimal risk of sudden death and low rate of reintervention for right ve

85 ticipatory planning for therapies to prevent sudden death and manage HF, is warranted.

86 nterpreting mtDNA variants in the context of sudden death and rare diseases.

87 nged its natural history, with prevention of sudden death and reversal of HF, thereby restoring quali

88 al aneurysms are at high risk for arrhythmic sudden death and thromboembolic events.

89 One death was cardiac sudden death and two were due to sepsis.

90 recommended programming accounted for 56% of sudden deaths and 11% of all deaths during the study per

91 Most sudden deaths and cardiac arrests occurred in the swim s

92 anism, and cause of death in the majority of sudden deaths and in almost 20% of nonsudden deaths.

93 magnetic conditions a series of entanglement sudden-deaths and revivals occur between the two qubits.

94 ts in the ibrutinib plus obinutuzumab group (sudden death) and one (1%) of 115 patients in the chlora

95 , 19 at low risk [age 30 (7.5); 12 males] of sudden death, and 15 healthy controls [age 37 (16); seve

96 th from stroke, 2.1 (95% CI, 1.5 to 2.9) for sudden death, and 3.5 (95% CI, 2.9 to 4.1) for death fro

97 Two (5%) had a previous episode of aborted sudden death, and 8 (20%) had syncope.

98 prednisone group (gastric ulcer perforation, sudden death, and cerebrovascular accident) and the plac

99 onary heart disease overall, out-of-hospital sudden death, and hospitalized ST-segment-elevation and

100 usly admitted to hospital, presumably due to sudden death, and in patients with poor left ventricular

101 f cardiovascular injury and the incidence of sudden death, and MR blockade decreases the risk of card

102 at baseline and (2) the incidence of death, sudden death, and other cardiac adverse events.

103 ardioverter-defibrillators for prevention of sudden death, and other contemporary treatment options.

104 gnificantly associated with (1) total death, sudden death, and pacemaker implantation in a model, inc

105 cardioverter-defibrillator for prevention of sudden death are mainstays of therapy when deemed necess

106 Prior syncope and family history of sudden death are predictors of a positive genetic test.

107 Aborted sudden death as the first manifestation of the disease o

108 fety reports) presenting with aLQTS, TdP, or sudden death associated with ADT.

109 hondria as potential therapeutic targets for sudden death associated with cardiovascular disease.

110 The cumulative incidence of sudden death at 90 days after randomization was 2.4% in

111 t stopped all medications after pPCI), and 1 sudden death at home 9 months after pPCI.

112 pairment, testicular dysgenesis in males and sudden death at infant age by brainstem-mediated cardior

113 LQTS variants and identify risk factors for sudden death before birth.

114 ce showed markedly increased mortality, with sudden death beginning after 5 weeks and 100% mortality

115 </=5.7%, those with a SPRM-predicted risk of sudden death below the median had no reduction in mortal

116 with an increased risk of heart failure and sudden death, but its risk in patients with preserved le

117 The leading cause of mortality in HFpEF is sudden death, but little is known about the underlying m

118 r all decedents and within the categories of sudden death, cancer, congestive heart failure or chroni

119 hippocampus/amygdala and parahippocampus in sudden death cases and people at high risk, when compare

120 ents with a genetic form of exercise-induced sudden death (catecholaminergic polymorphic ventricular

121 WCD) for use and effectiveness in preventing sudden death caused by ventricular tachyarrhythmia or fi

122 Under conditions studied, sudden deaths caused by insulin-induced severe hypoglyce

123 brovascular accident) and the placebo group (sudden death, cerebrovascular accident, and pneumonia),

124 was performed (composite clinical outcome of sudden death, class III/IV heart failure, left ventricul

125 blockade of PI4KA in adult animals leads to sudden death closely correlating with the drug's ability

126 ver, despite its rarity and absence in large sudden death cohorts, TKOS remains a malignant and poten

127 type 1 patients is associated with total and sudden deaths, conduction defects, left ventricular dysf

128 Rates of sudden death declined substantially over time among ambu

129 d worse cardiac function, than those in whom sudden death did not occur.

130 by doxorubicin plus cyclophosphamide group), sudden death (docetaxel plus capecitabine followed by do

131 defibrillator discharges, resuscitated from sudden death, documented stroke, and admission for conge

132 luding implantable defibrillators to prevent sudden death, drugs and surgical myectomy (or, alternati

133 s in neonates, provoking brain damage and/or sudden death due to apnea episodes and cardiorespiratory

134 In college student-athletes, risk of sudden death due to cardiovascular disease is relatively

135 diac repolarization, associated high risk of sudden death due to ventricular tachycardia, and congeni

136 Two important causes of sudden death during endurance races are arrhythmic death

137 ped to improve the sleep quality and prevent sudden death during sleep.

138 ex, clinical presentation, family history of sudden death, ethnicity, and deprivation index did not p

139 The sudden death event rate was 4.7%/year.

140 There were no arrhythmic sudden death events among the 217 patients with ICD.

141 The rate of sudden death fell from 12.15% with conventional care to

142 ge, NYHA functional class, family history of sudden death (FHSD), syncope, atrial fibrillation, non-s

143 EG suppression, cardiorespiratory arrest and sudden death following a seizure.

144 E and may represent an early risk factor for sudden death following SE.

145 ttributed to coronary heart disease, stroke, sudden death from an unknown cause, or a combination of

146 Only 5 of the 100 interrogated sudden death genes hosted actionable pathogenic mutation

147 laining the poor prognosis and propensity to sudden death has been elusive.

148 The risk of sudden death has changed over time among patients with s

149 gical connection between epilepsy itself and sudden death have fuelled increased attention to this ph

150 t explained by a substantially lower risk of sudden death (hazard ratio, 0.53 [0.43-0.65]; P<0.001).

151 onary syndrome, fatal myocardial infarction, sudden death, heart failure, coronary artery revasculari

152 alth-care expenditure as a result of stroke, sudden death, heart failure, unplanned hospital admissio

153 mortality (HR, 1.29 [1.05-1.59]; P=0.02) and sudden death (HR, 1.83 [1.24-2.69]; P<0.01) compared wit

154 rd ratio [HR], 1.58 [1.22-2.04]; P<0.01) and sudden death (HR, 2.12 [1.33-3.39]; P<0.01), compared wi

155 : 0.29; 95% CI: 0.12 to 0.73; p = 0.005) and sudden death (HR: 0.46; 95% CI: 0.20 to 1.07; p = 0.065)

156 ortic dissections are a preventable cause of sudden death if individuals at risk are identified and s

157 e patients (related to heart failure in 38%, sudden death in 5%, and other cardiovascular reason in 2

158 Sudden death in a family is associated with serious anxi

159 etes mellitus, and (2) all end points except sudden death in a model including all baseline character

160 associated with ventricular arrhythmias and sudden death in animal models and humans.

161 cular tachycardia (CPVT), a leading cause of sudden death in apparently healthy individuals exposed t

162 diomyopathy (HCM), a disease associated with sudden death in apparently healthy young adults.

163 uch sources as the U.S. National Registry of Sudden Death in Athletes (which uses news media, Interne

164 rts) from both the U.S. National Registry of Sudden Death in Athletes and the National Collegiate Ath

165 ardiographic screening for the prevention of sudden death in athletes.

166 LQTS is a known cause of sudden death in childhood, adolescence and young adultho

167 reliably define the incidence and causes of sudden death in college student-athletes.

168 ROS contribute to sudden death in diabetics after myocardial infarction by

169 Adjusted hazard ratios for sudden death in each trial group were calculated with th

170 Sudden death in heart failure patients is a major clinic

171 ting events, the incidence of sports-related sudden death in older adults is expected to rise.

172 in all-cause mortality, vascular death, and sudden death in patients with AF.

173 ibrillators (ICDs) for primary prevention of sudden death in patients with an ejection fraction (EF)

174 ibrillator (ICD) is effective for preventing sudden death in patients with hypertrophic cardiomyopath

175 of death due to ventricular tachyarrhythmias/sudden death in patients with nonischemic dilated cardio

176 Reports of sudden death in patients with normalized left ventricula

177 reases the risk of cardiovascular events and sudden death in patients with reduced glomerular filtrat

178 ventricular arrhythmias are a major cause of sudden death in patients with structural heart disease.

179 To explore the role of cardiac problems in sudden death in RTT, we characterized cardiac rhythm in

180 ting the increased risk for exertion-related sudden death in SCT carriers is unlikely related to fitn

181 ith a high incidence of arrhythmogenesis and sudden death in several cardiac diseases.

182 in the increased incidence of arrhythmia and sudden death in the ageing population.

183 ciated with life-threatening arrhythmias and sudden death in the athlete.

184 table arrhythmia syndrome or risk factor for sudden death in the context of other cardiac pathology.

185 children referred for evaluation following a sudden death in the family.

186 for and challenges of risk stratification of sudden death in the heart failure patient and discusses

187 h to pre-participation screening for risk of sudden death in the older athlete is a complex issue and

188 One patient died by sudden death in the placebo group.

189 represents the latest molecular autopsy for sudden death in the young (SDY).

190 sorder long QT syndrome (LQTS) can result in sudden death in the young or remain asymptomatic into ad

191 iomyopathy (HCM) is the most common cause of sudden death in the young, although not all patients eli

192 are often associated with increased risk of sudden death in the young.

193 genetic heart disease and a common cause of sudden death in the young.

194 ssel occlusions, myocardial infarctions, and sudden death in these mice.

195 is of clinical importance given the risk of sudden death in these patients, but so far contradictory

196 common cardiomyopathies and a major cause of sudden death in young athletes.

197 en without autopsy, familial screening after sudden death in young patients is effective.

198 ects the fact that ARVC is a common cause of sudden death in young people and that sudden death may b

199 Most sudden deaths in triathletes happened during the swim se

200 Methods to predict a higher or lower risk of sudden death include the detection of myocardial fibrosi

201 l Risk Model (SPRM) for proportional risk of sudden death, including death from ventricular arrhythmi

202 linked to severe diseases with high risk for sudden death, including epileptic encephalopathy and car

203 Sudden death is associated with failure of postnatal org

204 Premature, sudden death is devastating.

205 Sudden death is rare.

206 association of ventricular arrhythmias with sudden death led to significant investigation with antia

207 culated infrared absorption rates assuming a sudden-death limit.

208 As measurement of LVWT impacts diagnosis and sudden death management, CMR should be considered as par

209 use of sudden death in young people and that sudden death may be the first manifestation of the disea

210 Tragically, sudden death may be the first manifestation of the disea

211 teral prefrontal cortex (Brodmann Area 9) of sudden death medication-free individuals post mortem.

212 peritonitis, pneumothorax, septic shock, and sudden death (n=1 of each).

213 sustained ventricular tachycardia (n=1), or sudden death (n=1), compared with none of athletes with

214 red in 18 patients (3%; 0.54%/y): arrhythmic sudden death (n=12), progressive heart failure and heart

215 itis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durva

216 with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]).

217 cluding death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac tra

218 Although mechanisms of fentanyl-related sudden death need further investigation, blockade of hER

219 imaging, coronary obstruction, arrhythmias, sudden death, neoaortic regurgitation and dilation, neur

220 The overwhelming majority of sports-related sudden deaths occur among those older than 35 years of a

221 Over the 10-year study period, 182 sudden deaths occurred (age 20 +/- 1.7 years; 85% male;

222 ccurred, and 214% higher if an outbreak with sudden deaths occurred in the same month.

223 frequency with which cardiovascular-related sudden death occurs in competitive athletes importantly

224 After sudden death occurs in the young, first-degree family me

225 e interval, 1.6-9.7) and a family history of sudden death (odds ratio, 3.2; 95% confidence interval,

226 The sudden death of a previously healthy young individual is

227 ecameron contains a novella that details the sudden death of a young man called Gabriotto, including

228 that frequently is identified only after the sudden death of apparently healthy individuals.

229 The sudden death of young individuals is commonly attributed

230 ith adverse disease complications, including sudden death or heart failure death and a generally adve

231 eart failure (aHR, 2.24; 95% CI, 2.05-2.43), sudden death or ventricular arrhythmia (aHR, 1.69; 95% C

232 ssion was used to examine trends in rates of sudden death over time.

233 n by fewer deaths from myocardial infarction/sudden death (P<0.001) but not heart failure (P=0.85).

234 ructural changes potentially attributable to sudden death pathogenesis were present on magnetic reson

235 ed a longer mitral annulus disjunction in 50 sudden death patients with MVP and LV fibrosis than in 2

236 d by variants found in genes associated with sudden death-predisposing catecholaminergic polymorphic

237 many HCM patients, making the likelihood of sudden death prevention a reality and fulfilling the asp

238 oung, although not all patients eligible for sudden death prevention with an implantable cardioverter

239 table cardioverter-defibrillators (ICDs) for sudden death prevention, heart transplantation for end-s

240 e for HCM has demonstrated the potential for sudden death prevention, predominantly in adult patients

241 implantable cardioverter-defibrillators for sudden death prevention, thereby creating the opportunit

242 s, and one patient assigned fluoxetine had a sudden death (primary cause) with multiple sclerosis and

243 Children referred for a family history of sudden death receive cardiac disease diagnoses (14%), bu

244 trastructural changes, and long-term risk of sudden death remain unresolved and need further research

245 A total of 135 sudden deaths, resuscitated cardiac arrests, and trauma-

246 l fibrosis, although its role in stratifying sudden death risk in subgroups of HCM patients remains i

247 orphology index has the potential to improve sudden death risk stratification and patient selection f

248 its major disease pathways (i.e., arrhythmic sudden death risk; progressive heart failure [HF] due to

249 progressive heart failure (n=17); arrhythmic sudden death (SD) (n=17); and embolic stroke (n=2).

250 n suggested as the cause of up to a third of sudden death (SD) cases.

251 symptoms without the increased incidence of sudden death seen in adults treated with PDE3i.

252 lains the reported cardiac abnormalities and sudden death seen in humans with SCA.

253 Overall, 17 sudden death-susceptibility gene variants were identifie

254 epth of 10x across 90% of nucleotides within sudden death-susceptibility genes in 100% of parental ex

255 s of ultrarare, nonsynonymous variants in 99 sudden death-susceptibility genes.

256 AACEs included postdischarge sudden death, sustained ventricular tachycardia, and ven

257 liforme is a soil borne pathogen that causes sudden death syndrome (SDS) in soybean plants.

258 Sudden death syndrome (SDS), caused by Fusarium virgulif

259 Genetic mappings for soybean sudden death syndrome foliar chlorosis suggested that ST

260 ulation in Fusarium virguliforme that causes sudden death syndrome in soybean.

261 nutrient delivery and suppression of soybean sudden death syndrome.

262 to F. virguliforme, the pathogen that causes sudden death syndrome.

263 to a number of diseases, including epilepsy, sudden death syndromes like SUDEP and SIDS, and cardiac

264 inant syndrome of ventricular arrhythmia and sudden death that can present with divergent clinical fe

265 UDEP excludes other forms of seizure-related sudden death that might be mechanistically related (eg,

266 Sudden deaths that occurred out of hospital accounted fo

267 le cardioverter-defibrillators (ICDs) reduce sudden death, these patients die of heart failure (HF) o

268 Cardiomyopathy patients are at risk of sudden death, typically from scar-related abnormalities

269 nd 39 females) with >/=1 HCM risk factor for sudden death underwent S-ICD ECG screening at rest and o

270 alized for pneumonia are at greater risk for sudden death up to 1 year after infection.

271 01 genes implicated in cardiac disorders and sudden death using a postmortem blood sample.

272 ion of CIED alerts were noted when comparing sudden deaths versus nonsudden deaths (p < 0.001), defib

273 al and cardiac magnetic resonance studies in sudden death victims and patients with arrhythmic MVP.

274 adolescents with HCM judged at high risk for sudden death was assembled.

275 Their risk of sudden death was half that of men.

276 The rate of sudden death was not higher among patients with a recent

277 veillance of all genes (N=100) implicated in sudden death was performed to identify putative pathogen

278 Sudden death was reported in 3583 patients.

279 However, among patients who died, sudden death was, proportionally, the most common mode o

280 As fentanyl has a propensity to cause sudden death, we investigated its effects on the hERG ch

281 The minimum and median times to sudden death were 0.25 and 92 days, respectively.

282 diac mortality, heart failure mortality, and sudden death were 25.2%, 14.9%, 10.3%, 12.2%, and 2.1%,

283 The cumulative incidence rates of sudden death were assessed at different time points afte

284 on, and family history of cardiac disease or sudden death were collected.

285 sinus bradycardia, spontaneous seizure, and sudden death were detected in RQ/+ mutant mice in vivo;

286 Patients referred for a family history of sudden death were evaluated in a retrospective review fr

287 re at higher risk of all-cause mortality and sudden death when compared with those without CAD.

288 t failure morbidity or a cause of arrhythmic sudden death; when treated, it is associated with low di

289 Sudden death, where no end point illness is overt, is ob

290 function of hERG causes long QT syndrome and sudden death, which occur in patients with cardiac ische

291 high-risk patients susceptible to arrhythmic sudden death with a sensitivity of only 33%, leaving man

292 ents likely to achieve primary prevention of sudden death with implantable defibrillators.

293 autopsy studies report an associated risk of sudden death with interarterial anomalous left coronary

294 arrhythmic death syndrome (SADS) describes a sudden death with negative autopsy and toxicological ana

295 Sudden deaths with a prior clinical diagnosis of HCM but

296 etion of Slc8b1 in adult mouse hearts causes sudden death, with less than 13% of affected mice surviv

297 history of ventricular fibrillation (VF) and sudden death without electrocardiographic or echocardiog

298 neous disorders with the common phenotype of sudden death without explanation upon postmortem investi

299 many patients exposed to the possibility of sudden death without ICDs.

300 uction in mortality from other CV causes and sudden death, without apparent impact on HF deaths.